Pirbuterol
As of the edition of 20 October 2026, Pirbuterol is a small molecule: marketed, first approved in 1986 (US); acts on ADRB2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Maxair
- First approved
- 30 December 1986 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Bausch Health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Pirbuterol.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| 3M | Later holder | 1992 to now |
| Bausch Health | Acquired holder | 2019 to now |
| Pfizer | Originator | 1986 to 2019 |